SARS-CoV-2 and COVID-19 Research

This paper presents an optimized protocol for generating spike trans-complemented SARS-CoV-2 replicons with single-cycle infectivity in BSL-2 settings.

The paper identifies SARS-CoV-2 genetic markers associated with host domestication using a k-mer-based pipeline, revealing mutations and host-specific genomic patterns.

This study investigates how SARS-CoV-2 nsp14 proofreading affects nucleoside antiviral activity using genetic and pharmacological methods, finding that nsp14 attenuation increases sensitivity to nucleoside analogues.

The paper investigates the evolutionary origins of the BA.2.86 SARS-CoV-2 variant, finding it evolved through multiple transmission chains and recombination, not a single chronic infection.

This study identifies critical human host factors involved in SARS-CoV-2 multicycle replication through a genome-scale siRNA screen and validates potential antiviral targets.

This study identifies the dominant modes of SARS-CoV-2 shedding in the human respiratory tract across different infection phases using metagenomic data and a novel algorithm.

This paper shows that protein language models can assess mutation effects in SARS-CoV-2 spike protein without multiple sequence alignments, capturing evolutionary constraints and variant properties.

This study uses a library-on-library approach to analyze how a betacoronavirus antibody evolves breadth through somatic hypermutations, identifying key mutations that improve binding across multiple antigenic variants.

This study identifies Malectin as a host factor that promotes coronavirus replication and viral protein biogenesis by interacting with viral nonstructural proteins.

This study shows that DNA aptamer nanomaterials can protect against diverse SARS-CoV-2 variants through respiratory mucosal administration, offering broad neutralization and superior protection compared to monoclonal antibodies.

This study reveals that SARS-CoV-2 nucleocapsid protein hyperphosphorylation by GSK-3 involves a complex, cooperative priming mechanism rather than simple sequential phosphorylation.

This study evaluates a hybrid vaccine combining influenza and SARS-CoV-2 antigens in rhesus macaques, showing strong immune responses and protection against SARS-CoV-2 infection.

This paper develops a volatile oil formula from traditional Chinese medicine that inhibits SARS-CoV-2 by targeting multiple viral and host proteins in cultured cells.

The paper validates repurposed drugs against SARS-CoV-2 using stem cell-derived cardiomyocyte and nasal epithelium models, confirming fluvoxamine's antiviral efficacy in combination with other drugs.

This study identifies an ACE2-independent pathway for sarbecovirus entry in human cells, mediated by TMPRSS2-related proteases and linked to reduced antibody neutralization.

The paper evaluates neutralising antibody titres against SARS-CoV-2 variant JN.1 using live-virus microneutralisation assays in vaccinated individuals, finding higher titres in monovalent vaccine recipients.

This study uses AlphaFold2 and molecular dynamics to predict conformational ensembles and binding mechanisms of SARS-CoV-2 Omicron variants, showing agreement with experimental data.

This study shows that non-active site mutations in SARS-CoV-2 Mpro enhance dimer-dimer interactions, aiding substrate binding and resistance to nirmatrelvir.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

This paper develops a Bayesian weighted scheme to predict SARS-CoV lineage evolution and demonstrates its retrospective application to anticipate SARS-CoV-2 emergence from SARS-CoV-1.

This study investigates SARS-CoV-2 neutralising antibodies in sheep exposed to the virus, finding partial neutralisation against Wuhan and Delta variants but escape in Omicron variants, suggesting cross-species transmission risks.

The paper identifies ligands binding to the SARS-CoV-2 nsp10-16 complex using X-ray crystallography and reports their structures, providing insights for drug discovery.

The paper examines how different SARS-CoV-2 variants bind to the human ACE2 receptor, identifying regions of ACE2 involved in binding and suggesting multiple binding sites contribute to interaction.

The paper investigates the interaction between SARS-CoV-2 spike RBD and membrane-bound ACE2, showing rapid internalization and ACE2 downregulation, with variant-specific differences in binding dependencies.

The paper analyzes SARS-CoV-2 genomic variants from hospitalized severe pneumonia patients in Mexico, identifying mutations associated with increased mortality.

This study shows ORF8 suppresses viral particle production by interacting with Spike and causing Golgi fragmentation, supporting evolutionary pressure to delete ORF8 in SARS-CoV-2 variants.

The paper investigates tissue-specific metabolic reprogramming and gut dysbiosis in hamsters infected with SARS-CoV-2 variants, revealing differences in viremia, metabolic responses, and microbiota composition between delta and omicron variants.

This study shows that prior malaria exposure in K18-hACE2 mice reduces SARS-CoV-2 mortality without affecting lung viral load.

This study characterizes SARS-CoV-2 BA.5 variants in H11-K18 hACE2 golden hamsters, showing disease progression and severity similar to human infections, supporting the model's utility for research.

This study evaluates immune escape and replicative capacity of Omicron variants in human airway epithelial cells and sera from diverse immunological backgrounds.